Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Comments Comments
  •  (3)
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

Understanding and Managing Peripheral Neuropathy

Winter/Spring 2010

 < Prev  |  1  |  2  |  3  |  4 

Conclusion

DSPN remains a pervasive problem for people with HIV in the HAART era. The risk of developing peripheral neuropathy can be minimized by detecting HIV disease early to allow for appropriate monitoring of viral load and immune status, as well as timely initiation of antiretroviral treatment. Working with a knowledgeable care provider, HIV patients today can construct effective modern combination regimens that avoid neurotoxic drugs.

Further research is needed to develop additional options for neuropathy prevention and treatment. However, when DSPN does occur, it can be managed in an individualized manner using a wide range of agents for pain control. Researchers are also working on future therapies that may enable nerve regeneration and reversal of existing damage.

Anne Monroe, M.D., M.S.P.H., is a board-certified internist providing clinical care to HIV positive individuals. Her research interests include the prevention and treatment of sexually transmitted infections and HIV-related illnesses and conditions.


Selected Sources

  1. Abrams D and others. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 68:515-21. February 13, 2007.
  2. Ances B and others. Role of metabolic syndrome components in HIV-associated sensory neuropathy. AIDS 23(17):2317-22. November 13, 2009.
  3. Arenas-Pinto A and others. The risk of developing peripheral neuropathy induced by nucleoside reverse transcriptase inhibitors over time: evidence from the Delta trial. Antiviral Therapy 13(2):289-95. 2008.
  4. Cherry C and others. Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort. Neurology 66:867-73. March 28, 2006.
  5. Cherry C and others. Co-enzyme Q10 is superior to acetyl-L-carnitine for preventing NRTI-associated toxic neuropathy in an in vitro model. 16th Conference on Retroviruses and Opportunistic Infections (CROI). Montreal, Canada. February 8-11, 2009. Abstract 447.
  6. Cherry C and others. Predicting neuropathy risk before stavudine prescription: an algorithm for minimizing neurotoxicity in resource-limited settings. 16th CROI. Abstract 161.
  7. Estanislao L and others. HIV neuromuscular disease and mitochondrial function. Mitochondrion 4(2-3):131-9. July 2004.
  8. Evans S and others. A randomized trial evaluating Prosaptide for HIV-associated sensory neuropathies: use of an electronic diary to record neuropathic pain. PLoS ONE 2(6):e551. July 25, 2007.
  9. Gonzalez-Duarte A and others. Diagnosis and management of HIV-associated neuropathy. Neurologic Clinics 26(3):821-32. August 2008.
  10. Hahn K and others. A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. Journal of Neurology 251(10):1260-6. October 2004.
  11. Hung C and others. Impact of long-term treatment with neurotoxic dideoxynucleoside antiretrovirals: implications for clinical care in resource-limited settings. HIV Medicine 9(9):731-7. October 2008.
  12. Lichtenstein K and others. Initiation of antiretroviral therapy at CD4 cell counts ≥350 cells/mm3 does not increase incidence or risk of peripheral neuropathy, anemia, or renal insufficiency. JAIDS 47(1):27-35. January 2008.
  13. McArthur J and others. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291. Neurology 54(5):1080-8. March 14, 2000.
  14. Schifitto G and others. Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy. Neurology 57(7):1313-6. October 9, 2001.
  15. Schifitto G and others. A placebo-controlled study of memantine for the treatment of human immunodeficiency virus-associated sensory neuropathy. Journal of Neurovirology 12(4):328-31. August 2006.
  16. Simpson D and others. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology 70(24):2305-13. June 10, 2008.
  17. Simpson D and others. Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology 60(9):1508-14. May 13, 2003.
  18. Sultan A and others. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurology 8:29. August 1, 2008.
  19. Valcour V and others. Acetyl-l-carnitine and nucleoside reverse transcriptase inhibitor-associated neuropathy in HIV infection. HIV Medicine 10(2):103-10. February 2009.
 < Prev  |  1  |  2  |  3  |  4 


  
  • Email Email
  • Comments Comments
  •  (3)
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

This article was provided by San Francisco AIDS Foundation. It is a part of the publication Bulletin of Experimental Treatments for AIDS. Visit San Francisco AIDS Foundation's Web site to find out more about their activities, publications and services.
 
See Also
Neurological Complications of AIDS Fact Sheet
More on Neuropathy
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you

 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement